<DOC>
	<DOCNO>NCT00015951</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody bevacizumab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining monoclonal antibody therapy chemotherapy may effective treatment hematologic cancer . PURPOSE : Phase II trial study effectiveness bevacizumab combine cytarabine mitoxantrone treat patient hematologic cancer .</brief_summary>
	<brief_title>Bevacizumab , Cytarabine , Mitoxantrone Treating Patients With Hematologic Cancers</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical effectiveness bevacizumab , cytarabine , mitoxantrone patient poor-risk hematologic malignancy . - Determine toxic effect regimen patient . - Determine whether regimen induce cell apoptosis patient . - Determine effect bevacizumab coagulation profile patient . OUTLINE : This multicenter study . Patients receive cytarabine IV continuously 72 hour day 1-3 , mitoxantrone IV 30-60 minute day 4 , bevacizumab IV 90 minute day 8 absence disease progression unacceptable toxicity . Patients achieve partial complete remission may receive second course therapy begin approximately 30 day completion first course . Patients follow death . PROJECTED ACCRUAL : A total 12-45 patient accrue study within 1-3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm poorrisk hematologic malignancy Relapsed refractory acute myelogenous leukemia ( AML ) Primary induction failure Myelodysplasia ( MDS ) relate AML Secondary AML Relapsed refractory MDS Primary induction failure Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Chronic myelogenous leukemia blast crisis Failure prior primary induction therapy relapse achieve complete remission allow 3 course prior induction/reinduction therapy receive No hyperleukocytosis ( 50,000 leukemic blasts/mm3 ) No active CNS leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics No disseminate intravascular coagulation Hepatic : AST/ALT great 2 time normal Alkaline phosphatase great 2 time normal Bilirubin great 1.5 time normal Renal : Creatinine great 1.5 time normal Cardiovascular : LVEF least 45 % MUGA echocardiogram No myocardial infarction within past 3 month No history severe coronary artery disease No cardiomyopathy No New York Heart Association class III IV heart disease ( congestive heart failure ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active uncontrolled infection No history cytarabinerelated neurotoxicity No evidence graftversushost disease PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior hematopoietic growth factor include epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) At least 1 week since prior interleukin3 interleukin11 At least 4 week since prior autologous stem cell transplantation At least 90 day since prior allogeneic stem cell transplantation No concurrent immunotherapy Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy recover No prior cytarabine administer 72hour continuous infusion follow mitoxantrone IV 30 minute No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : At least 2 week since prior immunosuppressive therapy No concurrent investigational commercially available antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>